NB
NBIX icon

NBT Bank’s Neurocrine Biosciences NBIX Stock Holding History

NBT Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69K Hold
10
– – ﹤0.01% 899
2026
Q1 		$1.32K Buy
+10
New +$1.33K ﹤0.01% 889
2025
Q2 		– Sell
-105
Closed -$11.6K – 815
2025
Q1 		$11.6K Hold
105
– – ﹤0.01% 645
2024
Q4 		$14.3K Hold
105
– – ﹤0.01% 621
2024
Q3 		$12.1K Buy
+105
New +$14.4K ﹤0.01% 672

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NBT Bank's NBIX Position: Q2 2026 in Review

NBT Bank held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 10 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #899.

NBT Bank first reported a position in NBIX in Q3 2024 and has held it in 5 quarters since. The position peaked at $14.3K in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • NBT Bank held 10 shares of Neurocrine Biosciences worth $1.69K as of Q2 2026.
  • NBT Bank left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of NBT Bank's portfolio in Q2 2026, its #899 holding.
  • NBT Bank first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 5 quarters since.
  • NBT Bank's Neurocrine Biosciences position peaked at $14.3K in Q4 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on NBT Bank's 13F filing for Q2 2026, filed 29 Jul 2026.